Dystonia Clinical Trials
Here are the 6 most popular medical studies for dystonia
Procedure
DBS Surgery for Hand Dystonia
This trial is testing a new procedure to treat focal hand dystonia, a condition that causes involuntary muscle movements. A device is placed in the chest and attached to wires in the brain, which stimulating the areas affected by dystonia can help to block nerve signals and improve symptoms.
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
AUSTEDO for Dystonia
This trial is testing the safety and effectiveness of AUSTEDO in people with dystonia. The study will last up to 13 weeks, and participants will be monitored for side effects throughout.
Real NIBS for Cervical Dystonia
Cervical dystonia (CD) is a common movement disorder. Despite the optimization of botulinum toxin injection (BoNT-A) parameters including muscle selection and dosing, a significant proportion of patients report low levels of satisfaction, and a few of them develop resistance to therapy. The only options for such patients would be invasive therapy such as pallidotomy or pallidal deep brain stimulation. Currently, studies are going on the effectiveness of noninvasive neurostimulation in different neurological disorders. Transcranial Direct Current Stimulation (tDCS) or transcranial pulsed current stimulation (tPCS) are known to be safe non-invasive intervention with almost no side effects that can be used to provide complementary treatment. To detect the dysfunctional regions five min resting state quantitative EEG (qEEG) eyes closed will be recorded and analyzed each time before and after noninvasive stimulation. The investigators will evaluate the efficacy of acute noninvasive stimulation in those CD patients who are already on 3 monthly BoNT-A therapy but the effect of BoNT-A is wearing off in 8 weeks. Kinematics (static and dynamic movements) of neck movements will be recorded using established technology before and after stimulation.
Neurotoxin
Botulinum Toxin Type A for Cervical Dystonia
This study investigates the use of a kinematic measurement device to quantify the abnormal head movements and postures in patients with cervical dystonia (CD) in order to individualize and optimize botulinum toxin type A (BoNT-A) injection therapy. A single sensor captures five degrees of freedom of the neck and head that distinguish which muscle(s) contribute to CD and the amount of BoNT-A to inject into these muscle(s). The efficacy, relief and improvements in social, occupation and function by injections will be investigated. The efficacy of BoNT-A therapy using either BoNT-A injection parameters from clinical-based assessments and kinematically-based assessments will be investigated in CD patients. Individuals clinically diagnosed with CD will be randomized for two treatment conditions: A) injection parameters from a kinematic assessment only, or B) injection parameters from a clinical assessment only.
Popular filter options for dystonia trials
View More Dystonia Trials
See another 11 medical studies focused on dystonia.
Frequently Asked Questions
Introduction to dystonia
What are the top hospitals conducting dystonia research?
In the realm of dystonia research, several distinguished hospitals are leading the way in advancing our understanding and treatment of this complex neurological condition. The Toronto Western Hospital in Canada stands out with three active clinical trials dedicated to dystonia, alongside seven completed trials since their first recorded investigation back in 2006. Across the border in Boston, two institutions are making significant strides as well. At the Massachusetts Eye and Ear Infirmary, researchers are currently conducting two ongoing dystonia trials while having achieved four previous studies since they embarked on their first trial in 2015. Meanwhile, at the renowned Massachusetts General Hospital, experts have initiated two active dystonia trials thus far but made a remarkable impact despite their relative newness by starting it's pioneering investigation merely last year during2020.
Further down south at the National Institutes of Health Clinical Center located in Bethesda has accomplished an impressive nine completed dystonia trials for innovation-oriented individuals running such experiments since all time from recording times back until2009.The London Health Sciences Centre may appear smaller-scale with only two current clinical tests ongoing and three previously held investigations; theirs can be traced back only a decade ago to2012.
Dystonia is a challenging condition characterized by involuntary muscle contractions that cause repetitive or twisting movements. It can affect various parts of the body and lead to significant pain and functional impairments for those living with it. These top hospitals' commitment to exploring novel approaches and therapies through clinical trials offers hope for improved outcomes and quality of life for individuals affected by dystonia worldwide. By delving into these innovative studies and expanding our knowledge base about this intricate disorder under different settings from across North America up until Europe; we advance towards more effective treatments while moving closer towards finding eventual cure
Which are the best cities for dystonia clinical trials?
In the realm of dystonia clinical trials, several cities emerge as prime locations for innovative research. Boston, Massachusetts takes the lead with 7 active trials investigating interventions like Deep Brain Stimulation and DystoniaNet-based diagnosis. Toronto, Ontario follows closely behind with 5 ongoing studies exploring treatments such as Transcranial ExAblate System and Active Low Intensity Transcranial Focused ultrasound. Gainesville, Florida also makes its mark with 3 active trials delving into approaches like Active biphasic pulse stimulation and progressive resistance exercise. Additionally, Bethesda, Maryland contributes to the field with 3 active trials focusing on treatment arm options and DBS surgery. While San Francisco, California boasts 2 active trials centered around Deep Brain Stimulation and targeted patients with Parkinson's disease GP Target. These cities serve as hotspots for individuals seeking participation in cutting-edge dystonia clinical trials that pave the way for advancements in care and improved quality of life.
Which are the top treatments for dystonia being explored in clinical trials?
Exploration of clinical trials for dystonia has identified two top treatments showing promise in recent research. DystoniaNet-based diagnosis of isolated dystonia is currently being tested in one active trial, marking its debut in the field with a single all-time dystonia trial since 2022. Deep Brain Stimulation, on the other hand, has gained attention with one ongoing trial and a total of six historic dystonia trials since its introduction back in 2011. These groundbreaking treatments offer hope to patients living with this challenging neurological disorder as researchers strive for advancements and improved outcomes.
What are the most recent clinical trials for dystonia?
Recent clinical trials offer promising prospects for individuals living with dystonia. One such trial focuses on Ingrezza, a medication undergoing Phase 4 testing, which has shown potential benefits in the management of dystonia symptoms. Additionally, botulinum toxin type A is being evaluated in Phase 2 and Phase 3 studies as a potential treatment option for this condition. Another trial investigates deutetrabenazine 6 MG and its efficacy in alleviating dystonia symptoms. Furthermore, deep brain stimulation (DBS) surgery is being explored as a possible intervention for managing dystonia. Although these trials have varying phases and availability dates ranging from as recent as October 2021 to earlier years like January 2018 or even January 2016, they collectively contribute to advancing our understanding of dystonia treatment options moving forward.
What dystonia clinical trials were recently completed?
Two noteworthy clinical trials investigating potential treatments for dystonia have recently concluded, signifying significant progress in the field. In July 2021, AEON Biopharma successfully completed a trial focusing on ABP-450. This was followed by another trial involving ABP-450 sponsored by AEON Biopharma in March 2021. These recent advancements bring hope to individuals living with dystonia and highlight the commitment of researchers towards finding effective therapies for this challenging condition.